Google Finance Hzn

HZNP, now known as Amneal Pharmaceuticals (AMRX), used to be a ticker symbol on Google Finance, representing Horizon Therapeutics. A pharmaceutical company focused on developing and commercializing medicines to address unmet needs, particularly in rare, autoimmune, and inflammatory diseases. However, in November 2023, Amneal Pharmaceuticals completed its acquisition of Horizon Therapeutics, resulting in the delisting of HZNP and its subsequent replacement by AMRX. Therefore, searching “Google Finance HZNP” will now primarily provide historical data related to Horizon Therapeutics before the acquisition.

Historical Significance of HZNP: Before its acquisition, HZNP was a publicly traded company frequently monitored by investors interested in the biotechnology and pharmaceutical sectors. Its stock performance reflected the company’s clinical trial results, regulatory approvals, and market penetration of its key drugs. Investors closely watched metrics such as revenue growth, earnings per share (EPS), and pipeline development to gauge the company’s future prospects.

Key Products and Therapeutic Areas: Horizon Therapeutics had a diverse portfolio of medications targeting various conditions. These included:

• Tepezza: Used for the treatment of Thyroid Eye Disease (TED). Tepezza became a significant revenue driver for Horizon and played a crucial role in its growth story.
• Krystexxa: A treatment for uncontrolled gout.
• Ravicti: Used in the management of urea cycle disorders (UCDs).

The success of these and other drugs contributed to the stock’s performance and overall market valuation. Investors on Google Finance could track HZNP’s stock price, volume, market capitalization, and other relevant financial information to make informed investment decisions.

Impact of Acquisition by Amneal: The acquisition of Horizon Therapeutics by Amneal Pharmaceuticals represented a significant shift for both companies. Amneal, a generics and specialty pharmaceutical company, significantly expanded its portfolio and pipeline with the addition of Horizon’s innovative therapies. The combined entity, trading under the AMRX ticker, aims to leverage synergies and create a broader, more diversified pharmaceutical business.

Information Now Available on Google Finance: Now, when searching on Google Finance, investors should use the AMRX ticker to track the performance of the combined company. Historical data for HZNP remains accessible, providing a record of Horizon Therapeutics’ past performance. However, to follow the current market trends and financial health of the merged entity, AMRX is the relevant ticker. This data includes updated stock quotes, news articles, financial statements, and key ratios, allowing investors to analyze the post-acquisition performance of Amneal Pharmaceuticals with the added assets of Horizon Therapeutics.

In summary, HZNP on Google Finance provides a historical snapshot of Horizon Therapeutics. To understand the current performance of the combined company, investors should focus on AMRX. The acquisition marked a significant transition, altering the landscape of both companies and creating a new entity with a broader range of therapeutic offerings.